

# IMMUNE-MEDIATED LIVER DISEASE SPECIAL INTEREST GROUP (SIG):

The inaugural meeting of the SIG was held on the 11<sup>th</sup> of July 2019, Birmingham, 41 participants.

## **Key action points**

#### **Observational cohort studies:**

All nominated proposals were discussed, with an understanding that each project would have a nominated principal investigator and designated research fellow to carry out the work. Each PI was asked to submit a 1-page study outline (including timelines and protocol if possible) by the BASL annual meeting 2019.

# 1) Nationwide experience and outcomes of overlap presentations in autoimmune liver disease Omar El-Sherif (Birmingham/Dublin)

- Multicentre retrospective observational cohort study
- Case record form to be shared with the study outline / proposal by <u>October</u> <u>2019</u>. This will be circulated to all steering committee members for approval, and then to all BASL members in order to gauge feasibility and willingness to participate (<u>December 2019</u>)
- A dedicated study coordinator will be appointed to facilitate day-to-day running of the project (February 2019)
- Specific study questions within this initiative were discussed at the meeting:
  - (a) gauge the prevalence (and discrepancy between centres) of overlap presentations submitted to PBC ODNs for consideration of second-line therapy;
  - (b) determine the prognostic impact of biliary lesions histologically in AIH; and
  - (c) present the phenotypic variants associated with age at presentation in AIH and PSC.

# 2) Impact of AILD on sexual dysfunction and relationship status

Michael Heneghan (London)

- Initiative to study the impact of all AILD on sexual dysfunction and relationship status using tools currently available in inflammatory bowel disease, was proposed
- PBC foundation, AIH Support and PBC Support to conduct a Survey Monkey 'snapshot' in conjunction with MH, to generate preliminary data prior to moving forward with a dedicated multi-centre exercise.

## 3) Stratification of high-risk groups toward developing recurrent PSC

James Ferguson (Birmingham)

- Prospective registry study across all liver transplant centres in the UK, with a view to define and stratify the highest at-risk group of developing recurrence; eligibility from 1 year post transplant DBD recipients only
- Likely to apply a machine-learning algorithm to risk-predict (expertise available locally)



- Case record form to be shared with the study outline / proposal in <u>October 2019</u>. This will be circulated to all steering committee members for approval, and then to all BASL members in order to gauge feasibility and willingness to participate (<u>December 2019</u>)
- A dedicated study coordinator will be appointed to facilitate day-to-day running of the project (**February 2019**).

## 4) Epidemiological survey of patients with IgG4-RD in the UK

Emma Culver (Oxford)

- Plans for a nationwide study to determine the incidence and prevalence of IgG4-related disease were put forward
- EC to circulate study proposal and timelines to the SIG committee after the summer.

#### **Educational events**

1) UK-PSC Study Day

Friday 25th October; Leeds

#### 2) Falk meeting; Autoimmune Liver Disease

Friday 20th March; Birmingham

## **Grant bids in development**

## 1) EASL registry grant: checkpoint-inhibitor induced liver injury

Palak Trivedi (Birmingham)

Guruprasad Aithal (Nottingham)

# 2) NIHR HS&DR scheme: Effective, efficient and equitable management in AILD

David Jones (Newcastle)

Palak Trivedi (Birmingham)

George Mells (Cambridge)

Jessica Dyson (Newcastle)

# 3) NIHR HTA scheme: Optimised primary therapy in PBC

Dave Jones (Newcastle)

#### **Further information**

Please visit the SIG webpage at https://www.basl.org.uk/index.cfm/content/page/cid/39.